ReviewFrontiers in allergy2026
Persistence, chronicity, and recurrence of infection-associated urticaria following viral infections in children and adults: a systematic review.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viral infections are recognized triggers of acute urticaria; however, the long-term outcomes of infection-associated urticaria, including persistence, recurrence, and progression to chronic disease, remain incompletely characterized. Objective: To systematically review the available evidence on the persistence, chronicity, and recurrence of infection-associated urticaria following viral infections in children and adults. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420261319656). Electronic databases (PubMed, Embase, CINAHL, Scopus, and Web of Science) were searched from inception to 17 March 2026. Observational studies reporting long-term outcomes of infection-associated urticaria following viral infection were included. Data extraction and risk of bias assessment using the Newcastle-Ottawa Scale were performed independently by two reviewers. Due to substantial heterogeneity, findings were synthesized narratively. Results: Five studies involving 596 participants were included. Most cases of infection-associated urticaria occurred during the acute phase of infection and resolved within weeks to months. However, persistence beyond 6 months was reported in up to 9.5% of cases, and a small proportion demonstrated persistent symptoms extending beyond 1 year. Reported recurrence and chronicity rates ranged from approximately 7% to 30%, although several estimates were derived from mixed-etiology cohorts in which infection-related cases were not analyzed separately. Delayed-onset urticaria, particularly following SARS-CoV-2 infection, was associated with an increased likelihood of progression to chronic spontaneous urticaria. However, interpretation is limited by the inclusion of mixed-etiology cohorts in which viral infection was not always laboratory-confirmed or analyzed separately. Conclusion: Infection-associated urticaria is typically self-limiting; however, a small but potentially clinically relevant subset of patients may develop persistent or chronic symptoms. Recognition of potential risk patterns, particularly delayed-onset urticaria in the context of SARS-CoV-2 infection, may support improved patient counselling and follow-up. Current evidence remains limited by heterogeneous study designs, mixed aetiologies, and inconsistent pathogen-specific reporting. Further prospective studies with standardized definitions and pathogen-specific analyses are needed. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=1319656, identifier CRD420261319656.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.